1	1	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Introduction	_	_	NN	_	_	_	_	_


1	Cancer	_	_	NNP	_	_	_	_	_
2	has	_	_	VBZ	_	_	_	_	_
3	been	_	_	VBN	_	_	_	_	_
4	a	_	_	DT	_	_	_	_	_
5	major	_	_	JJ	_	_	_	_	_
6	threat	_	_	NN	_	_	_	_	_
7	to	_	_	TO	_	_	_	_	_
8	human	_	_	JJ	_	_	_	_	_
9	health	_	_	NN	_	_	_	_	_
10	in	_	_	IN	_	_	_	_	_
11	recent	_	_	JJ	_	_	_	_	_
12	years	_	_	NNS	_	_	_	_	_
13	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	past	_	_	JJ	_	_	_	_	_
4	forty	_	_	CD	_	_	_	_	_
5	years	_	_	NNS	_	_	_	_	_
6	,	_	_	,	_	_	_	_	_
7	even	_	_	RB	_	_	_	_	_
8	though	_	_	IN	_	_	_	_	_
9	great	_	_	JJ	_	_	_	_	_
10	efforts	_	_	NNS	_	_	_	_	_
11	have	_	_	VBP	_	_	_	_	_
12	been	_	_	VBN	_	_	_	_	_
13	made	_	_	VBN	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	there	_	_	EX	_	_	_	_	_
16	is	_	_	VBZ	_	_	_	_	_
17	still	_	_	RB	_	_	_	_	_
18	much	_	_	JJ	_	_	_	_	_
19	to	_	_	TO	_	_	_	_	_
20	be	_	_	VB	_	_	_	_	_
21	done	_	_	VBN	_	_	_	_	_
22	before	_	_	IN	_	_	_	_	_
23	a	_	_	DT	_	_	_	_	_
24	safe	_	_	JJ	_	_	_	_	_
25	therapy	_	_	NN	_	_	_	_	_
26	is	_	_	VBZ	_	_	_	_	_
27	achieved	_	_	VBN	_	_	_	_	_
28	.	_	_	.	_	_	_	_	_


1	Currently	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	chemotherapy	_	_	NN	_	_	_	_	_
4	and	_	_	CC	_	_	_	_	_
5	radiotherapy	_	_	NN	_	_	_	_	_
6	are	_	_	VBP	_	_	_	_	_
7	still	_	_	RB	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	main	_	_	JJ	_	_	_	_	_
10	therapeutic	_	_	JJ	_	_	_	_	_
11	methods	_	_	NNS	_	_	_	_	_
12	for	_	_	IN	_	_	_	_	_
13	cancer	_	_	NN	_	_	_	_	_
14	.	_	_	.	_	_	_	_	_


1	However	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	most	_	_	JJS	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	anticancer	_	_	JJ	_	_	_	_	_
7	drugs	_	_	NNS	_	_	_	_	_
8	have	_	_	VBP	_	_	_	_	_
9	toxic	_	_	JJ	_	_	_	_	_
10	side	_	_	NN	_	_	_	_	_
11	effects	_	_	NNS	_	_	_	_	_
12	.	_	_	.	_	_	_	_	_


1	Therefore	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	it	_	_	PRP	_	_	_	_	_
4	is	_	_	VBZ	_	_	_	_	_
5	critical	_	_	JJ	_	_	_	_	_
6	to	_	_	TO	_	_	_	_	_
7	develop	_	_	VB	_	_	_	_	_
8	novel	_	_	JJ	_	_	_	_	_
9	anticancer	_	_	NN	_	_	_	_	_
10	drugs	_	_	NNS	_	_	_	_	_
11	that	_	_	WDT	_	_	_	_	_
12	have	_	_	VBP	_	_	_	_	_
13	no	_	_	DT	_	_	_	_	_
14	toxic	_	_	JJ	_	_	_	_	_
15	side	_	_	NN	_	_	_	_	_
16	effects	_	_	NNS	_	_	_	_	_
17	on	_	_	IN	_	_	_	_	_
18	other	_	_	JJ	_	_	_	_	_
19	tissues	_	_	NNS	_	_	_	_	_
20	or	_	_	CC	_	_	_	_	_
21	organs	_	_	NNS	_	_	_	_	_
22	in	_	_	IN	_	_	_	_	_
23	vivo	_	_	NN	_	_	_	_	_
24	,	_	_	,	_	_	_	_	_
25	and	_	_	CC	_	_	_	_	_
26	only	_	_	RB	_	_	_	_	_
27	target	_	_	VB	_	_	_	_	_
28	the	_	_	DT	_	_	_	_	_
29	lesion	_	_	NN	_	_	_	_	_
30	area	_	_	NN	_	_	_	_	_
31	.	_	_	.	_	_	_	_	_


1	Compared	_	_	VBN	_	_	_	_	_
2	with	_	_	IN	_	_	_	_	_
3	traditional	_	_	JJ	_	_	_	_	_
4	chemotherapeutic	_	_	JJ	_	_	_	_	_
5	drugs	_	_	NNS	_	_	_	_	_
6	,	_	_	,	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	nano-anticancer	_	_	JJ	_	_	_	_	_
9	drug	_	_	NN	_	_	_	_	_
10	therapy	_	_	NN	_	_	_	_	_
11	has	_	_	VBZ	_	_	_	_	_
12	potential	_	_	JJ	_	_	_	_	_
13	application	_	_	NN	_	_	_	_	_
14	prospects	_	_	NNS	_	_	_	_	_
15	in	_	_	IN	_	_	_	_	_
16	curing	_	_	VBG	_	_	_	_	_
17	cancer	_	_	NN	_	_	_	_	_
18	diseases	_	_	NNS	_	_	_	_	_
19	.	_	_	.	_	_	_	_	_


1	One	_	_	CD	_	_	_	_	_
2	of	_	_	IN	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	major	_	_	JJ	_	_	_	_	_
5	concerns	_	_	NNS	_	_	_	_	_
6	about	_	_	IN	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	nano-anticancer	_	_	JJ	_	_	_	_	_
9	drugs	_	_	NNS	_	_	_	_	_
10	is	_	_	VBZ	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	drug-delivery	_	_	NN	_	_	_	_	_
13	vector	_	_	NN	_	_	_	_	_
14	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	ideal	_	_	JJ	_	_	_	_	_
3	delivery	_	_	NN	_	_	_	_	_
4	vector	_	_	NN	_	_	_	_	_
5	should	_	_	MD	_	_	_	_	_
6	possess	_	_	VB	_	_	_	_	_
7	such	_	_	JJ	_	_	_	_	_
8	characteristics	_	_	NNS	_	_	_	_	_
9	as	_	_	IN	_	_	_	_	_
10	a	_	_	DT	_	_	_	_	_
11	high	_	_	JJ	_	_	_	_	_
12	drug-loading	_	_	NN	_	_	_	_	_
13	capacity	_	_	NN	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	low	_	_	JJ	_	_	_	_	_
16	immunogenicity	_	_	NN	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	low	_	_	JJ	_	_	_	_	_
19	toxicity	_	_	NN	_	_	_	_	_
20	,	_	_	,	_	_	_	_	_
21	better	_	_	JJR	_	_	_	_	_
22	shelf-life	_	_	NN	_	_	_	_	_
23	,	_	_	,	_	_	_	_	_
24	and	_	_	CC	_	_	_	_	_
25	water	_	_	NN	_	_	_	_	_
26	solubility	_	_	NN	_	_	_	_	_
27	,	_	_	,	_	_	_	_	_
28	and	_	_	CC	_	_	_	_	_
29	it	_	_	PRP	_	_	_	_	_
30	should	_	_	MD	_	_	_	_	_
31	have	_	_	VB	_	_	_	_	_
32	the	_	_	DT	_	_	_	_	_
33	potential	_	_	NN	_	_	_	_	_
34	to	_	_	TO	_	_	_	_	_
35	be	_	_	VB	_	_	_	_	_
36	further	_	_	RBR	_	_	_	_	_
37	modified	_	_	VBN	_	_	_	_	_
38	.	_	_	.	_	_	_	_	_


1	Synthetic	_	_	JJ	_	_	_	_	_
2	polymers	_	_	NNS	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	such	_	_	JJ	_	_	_	_	_
5	as	_	_	IN	_	_	_	_	_
6	,	_	_	,	_	_	_	_	_
7	chitosan	_	_	NN	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	polyetherimide	_	_	NN	_	_	_	_	_
10	(	_	_	-LRB-	_	_	_	_	_
11	PEI	_	_	NN	_	_	_	_	_
12	)	_	_	-RRB-	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	poly(lactic-co-glycolic	_	_	JJ	_	_	_	_	_
15	acid	_	_	NN	_	_	_	_	_
16	)	_	_	-RRB-	_	_	_	_	_
17	(	_	_	-LRB-	_	_	_	_	_
18	PLGA	_	_	NN	_	_	_	_	_
19	)	_	_	-RRB-	_	_	_	_	_
20	,	_	_	,	_	_	_	_	_
21	polyamidoamine	_	_	NN	_	_	_	_	_
22	(	_	_	-LRB-	_	_	_	_	_
23	PAMAM	_	_	NN	_	_	_	_	_
24	)	_	_	-RRB-	_	_	_	_	_
25	,	_	_	,	_	_	_	_	_
26	and	_	_	CC	_	_	_	_	_
27	poly-l-lactic	_	_	JJ	_	_	_	_	_
28	acid	_	_	NN	_	_	_	_	_
29	(	_	_	-LRB-	_	_	_	_	_
30	PLA	_	_	NNP	_	_	_	_	_
31	)	_	_	-RRB-	_	_	_	_	_
32	have	_	_	VBP	_	_	_	_	_
33	been	_	_	VBN	_	_	_	_	_
34	widely	_	_	RB	_	_	_	_	_
35	used	_	_	VBN	_	_	_	_	_
36	in	_	_	IN	_	_	_	_	_
37	gene-	_	_	JJ	_	_	_	_	_
38	and	_	_	CC	_	_	_	_	_
39	drug-delivery	_	_	NN	_	_	_	_	_
40	systems	_	_	NNS	_	_	_	_	_
41	.	_	_	.	_	_	_	_	_


1	However	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	stability	_	_	NN	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	sustained-release	_	_	JJ	_	_	_	_	_
6	formulations	_	_	NNS	_	_	_	_	_
7	in	_	_	IN	_	_	_	_	_
8	aqueous	_	_	JJ	_	_	_	_	_
9	solution	_	_	NN	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	long	_	_	JJ	_	_	_	_	_
12	delivery	_	_	NN	_	_	_	_	_
13	times	_	_	NNS	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	low	_	_	JJ	_	_	_	_	_
17	delivery	_	_	NN	_	_	_	_	_
18	efficiency	_	_	NN	_	_	_	_	_
19	are	_	_	VBP	_	_	_	_	_
20	only	_	_	RB	_	_	_	_	_
21	a	_	_	DT	_	_	_	_	_
22	small	_	_	JJ	_	_	_	_	_
23	part	_	_	NN	_	_	_	_	_
24	of	_	_	IN	_	_	_	_	_
25	the	_	_	DT	_	_	_	_	_
26	challenges	_	_	NNS	_	_	_	_	_
27	highlighted	_	_	VBN	_	_	_	_	_
28	by	_	_	IN	_	_	_	_	_
29	researchers	_	_	NNS	_	_	_	_	_
30	.	_	_	.	_	_	_	_	_


1	Dendrigraft	_	_	NNP	_	_	_	_	_
2	poly-l-lysines	_	_	NNS	_	_	_	_	_
3	(	_	_	-LRB-	_	_	_	_	_
4	DGL	_	_	NNP	_	_	_	_	_
5	)	_	_	-RRB-	_	_	_	_	_
6	have	_	_	VBP	_	_	_	_	_
7	emerged	_	_	VBN	_	_	_	_	_
8	as	_	_	IN	_	_	_	_	_
9	a	_	_	DT	_	_	_	_	_
10	new	_	_	JJ	_	_	_	_	_
11	kind	_	_	NN	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	synthetic	_	_	JJ	_	_	_	_	_
14	polymer	_	_	NN	_	_	_	_	_
15	consisting	_	_	VBG	_	_	_	_	_
16	of	_	_	IN	_	_	_	_	_
17	lysine	_	_	NN	_	_	_	_	_
18	and	_	_	CC	_	_	_	_	_
19	have	_	_	VBP	_	_	_	_	_
20	been	_	_	VBN	_	_	_	_	_
21	employed	_	_	VBN	_	_	_	_	_
22	as	_	_	IN	_	_	_	_	_
23	drug-	_	_	NN	_	_	_	_	_
24	or	_	_	CC	_	_	_	_	_
25	gene-delivery	_	_	NN	_	_	_	_	_
26	carriers	_	_	NNS	_	_	_	_	_
27	,	_	_	,	_	_	_	_	_
28	due	_	_	JJ	_	_	_	_	_
29	to	_	_	TO	_	_	_	_	_
30	their	_	_	PRP$	_	_	_	_	_
31	biodegradability	_	_	NN	_	_	_	_	_
32	and	_	_	CC	_	_	_	_	_
33	rich	_	_	JJ	_	_	_	_	_
34	external	_	_	JJ	_	_	_	_	_
35	amino	_	_	NN	_	_	_	_	_
36	groups	_	_	NNS	_	_	_	_	_
37	that	_	_	WDT	_	_	_	_	_
38	can	_	_	MD	_	_	_	_	_
39	encapsulate	_	_	VB	_	_	_	_	_
40	drugs	_	_	NNS	_	_	_	_	_
41	by	_	_	IN	_	_	_	_	_
42	the	_	_	DT	_	_	_	_	_
43	emulsion	_	_	NN	_	_	_	_	_
44	crosslinking	_	_	VBG	_	_	_	_	_
45	method	_	_	NN	_	_	_	_	_
46	or	_	_	CC	_	_	_	_	_
47	plasmid	_	_	NN	_	_	_	_	_
48	DNA	_	_	NN	_	_	_	_	_
49	through	_	_	IN	_	_	_	_	_
50	electric	_	_	JJ	_	_	_	_	_
51	interactions	_	_	NNS	_	_	_	_	_
52	.	_	_	.	_	_	_	_	_


1	Besides	_	_	IN	_	_	_	_	_
2	their	_	_	PRP$	_	_	_	_	_
3	biodegradability	_	_	NN	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	they	_	_	PRP	_	_	_	_	_
6	can	_	_	MD	_	_	_	_	_
7	also	_	_	RB	_	_	_	_	_
8	be	_	_	VB	_	_	_	_	_
9	modified	_	_	VBN	_	_	_	_	_
10	with	_	_	IN	_	_	_	_	_
11	targeting	_	_	VBG	_	_	_	_	_
12	ligands	_	_	NNS	_	_	_	_	_
13	and	_	_	CC	_	_	_	_	_
14	polyethylene	_	_	NN	_	_	_	_	_
15	glycol	_	_	NN	_	_	_	_	_
16	(	_	_	-LRB-	_	_	_	_	_
17	PEG	_	_	NN	_	_	_	_	_
18	)	_	_	-RRB-	_	_	_	_	_
19	,	_	_	,	_	_	_	_	_
20	thereby	_	_	RB	_	_	_	_	_
21	rendering	_	_	VBG	_	_	_	_	_
22	vectors	_	_	NNS	_	_	_	_	_
23	with	_	_	IN	_	_	_	_	_
24	targeting	_	_	VBG	_	_	_	_	_
25	properties	_	_	NNS	_	_	_	_	_
26	and	_	_	CC	_	_	_	_	_
27	long	_	_	JJ	_	_	_	_	_
28	circulation	_	_	NN	_	_	_	_	_
29	.	_	_	.	_	_	_	_	_


1	As	_	_	IN	_	_	_	_	_
2	yet	_	_	RB	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	there	_	_	EX	_	_	_	_	_
5	are	_	_	VBP	_	_	_	_	_
6	only	_	_	RB	_	_	_	_	_
7	a	_	_	DT	_	_	_	_	_
8	few	_	_	JJ	_	_	_	_	_
9	ways	_	_	NNS	_	_	_	_	_
10	available	_	_	JJ	_	_	_	_	_
11	for	_	_	IN	_	_	_	_	_
12	targeted	_	_	VBN	_	_	_	_	_
13	delivery	_	_	NN	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	anticancer	_	_	JJ	_	_	_	_	_
16	drugs	_	_	NNS	_	_	_	_	_
17	.	_	_	.	_	_	_	_	_


1	Recently	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	a	_	_	DT	_	_	_	_	_
4	report	_	_	NN	_	_	_	_	_
5	showed	_	_	VBD	_	_	_	_	_
6	that	_	_	IN	_	_	_	_	_
7	VAR2CSA	_	_	NNP	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	which	_	_	WDT	_	_	_	_	_
10	is	_	_	VBZ	_	_	_	_	_
11	exposed	_	_	VBN	_	_	_	_	_
12	on	_	_	IN	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	membrane	_	_	NN	_	_	_	_	_
15	of	_	_	IN	_	_	_	_	_
16	Plasmodium	_	_	NN	_	_	_	_	_
17	falciparum	_	_	NN	_	_	_	_	_
18	infected	_	_	VBN	_	_	_	_	_
19	red	_	_	JJ	_	_	_	_	_
20	blood	_	_	NN	_	_	_	_	_
21	cells	_	_	NNS	_	_	_	_	_
22	(	_	_	-LRB-	_	_	_	_	_
23	iRBC	_	_	NNP	_	_	_	_	_
24	)	_	_	-RRB-	_	_	_	_	_
25	,	_	_	,	_	_	_	_	_
26	could	_	_	MD	_	_	_	_	_
27	bind	_	_	VB	_	_	_	_	_
28	to	_	_	TO	_	_	_	_	_
29	90	_	_	CD	_	_	_	_	_
30	%	_	_	NN	_	_	_	_	_
31	of	_	_	IN	_	_	_	_	_
32	tumors	_	_	NNS	_	_	_	_	_
33	,	_	_	,	_	_	_	_	_
34	which	_	_	WDT	_	_	_	_	_
35	was	_	_	VBD	_	_	_	_	_
36	verified	_	_	VBN	_	_	_	_	_
37	by	_	_	IN	_	_	_	_	_
38	running	_	_	VBG	_	_	_	_	_
39	immunohistochemistry	_	_	NN	_	_	_	_	_
40	on	_	_	IN	_	_	_	_	_
41	a	_	_	DT	_	_	_	_	_
42	tumor-tissue	_	_	NN	_	_	_	_	_
43	array	_	_	NN	_	_	_	_	_
44	.	_	_	.	_	_	_	_	_


1	Therefore	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	VAR2CSA	_	_	NNP	_	_	_	_	_
4	is	_	_	VBZ	_	_	_	_	_
5	becoming	_	_	VBG	_	_	_	_	_
6	an	_	_	DT	_	_	_	_	_
7	attractive	_	_	JJ	_	_	_	_	_
8	target	_	_	NN	_	_	_	_	_
9	for	_	_	IN	_	_	_	_	_
10	anticancer	_	_	NN	_	_	_	_	_
11	drugs	_	_	NNS	_	_	_	_	_
12	â€™	_	_	POS	_	_	_	_	_
13	development	_	_	NN	_	_	_	_	_
14	.	_	_	.	_	_	_	_	_


1	P.	_	_	NNP	_	_	_	_	_
2	falciparum	_	_	NNP	_	_	_	_	_


1	infection	_	_	NN	_	_	_	_	_
2	during	_	_	IN	_	_	_	_	_
3	pregnancy	_	_	NN	_	_	_	_	_
4	results	_	_	VBZ	_	_	_	_	_
5	in	_	_	IN	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	sequestration	_	_	NN	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	iRBC	_	_	NN	_	_	_	_	_
10	in	_	_	IN	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	placenta	_	_	NN	_	_	_	_	_
13	by	_	_	IN	_	_	_	_	_
14	adhering	_	_	VBG	_	_	_	_	_
15	to	_	_	TO	_	_	_	_	_
16	a	_	_	DT	_	_	_	_	_
17	distinct	_	_	JJ	_	_	_	_	_
18	type	_	_	NN	_	_	_	_	_
19	of	_	_	IN	_	_	_	_	_
20	chondroitin	_	_	NN	_	_	_	_	_
21	sulfate	_	_	NN	_	_	_	_	_
22	A	_	_	NN	_	_	_	_	_
23	(	_	_	-LRB-	_	_	_	_	_
24	CSA	_	_	NN	_	_	_	_	_
25	)	_	_	-RRB-	_	_	_	_	_
26	exclusively	_	_	RB	_	_	_	_	_
27	expressed	_	_	VBD	_	_	_	_	_
28	on	_	_	IN	_	_	_	_	_
29	trophoblast	_	_	NN	_	_	_	_	_
30	via	_	_	IN	_	_	_	_	_
31	VAR2CSA	_	_	NNP	_	_	_	_	_
32	.	_	_	.	_	_	_	_	_


1	Short	_	_	JJ	_	_	_	_	_
2	continuous	_	_	JJ	_	_	_	_	_
3	regions	_	_	NNS	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	VAR2CSA	_	_	NNP	_	_	_	_	_
6	with	_	_	IN	_	_	_	_	_
7	affinity	_	_	NN	_	_	_	_	_
8	for	_	_	IN	_	_	_	_	_
9	multiple	_	_	JJ	_	_	_	_	_
10	types	_	_	NNS	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	CSA	_	_	NN	_	_	_	_	_
13	were	_	_	VBD	_	_	_	_	_
14	defined	_	_	VBN	_	_	_	_	_
15	.	_	_	.	_	_	_	_	_


1	A	_	_	DT	_	_	_	_	_
2	28	_	_	CD	_	_	_	_	_
3	amino	_	_	NN	_	_	_	_	_
4	acids	_	_	NNS	_	_	_	_	_
5	placenta	_	_	NN	_	_	_	_	_
6	CSA-binding	_	_	NN	_	_	_	_	_
7	peptide	_	_	NN	_	_	_	_	_
8	(	_	_	-LRB-	_	_	_	_	_
9	plCSA-BP	_	_	NNP	_	_	_	_	_
10	)	_	_	-RRB-	_	_	_	_	_
11	from	_	_	IN	_	_	_	_	_
12	the	_	_	DT	_	_	_	_	_
13	VAR2CSA	_	_	NNP	_	_	_	_	_
14	region	_	_	NN	_	_	_	_	_
15	was	_	_	VBD	_	_	_	_	_
16	recently	_	_	RB	_	_	_	_	_
17	tested	_	_	VBN	_	_	_	_	_
18	as	_	_	IN	_	_	_	_	_
19	a	_	_	DT	_	_	_	_	_
20	guide	_	_	NN	_	_	_	_	_
21	peptide	_	_	NN	_	_	_	_	_
22	for	_	_	IN	_	_	_	_	_
23	targeted	_	_	VBN	_	_	_	_	_
24	delivery	_	_	NN	_	_	_	_	_
25	of	_	_	IN	_	_	_	_	_
26	doxorubicin	_	_	NN	_	_	_	_	_
27	to	_	_	TO	_	_	_	_	_
28	choriocarcinoma	_	_	NN	_	_	_	_	_
29	.	_	_	.	_	_	_	_	_


1	However	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	whether	_	_	IN	_	_	_	_	_
4	it	_	_	PRP	_	_	_	_	_
5	could	_	_	MD	_	_	_	_	_
6	be	_	_	VB	_	_	_	_	_
7	used	_	_	VBN	_	_	_	_	_
8	to	_	_	TO	_	_	_	_	_
9	modify	_	_	VB	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	DGL	_	_	NNP	_	_	_	_	_
12	and	_	_	CC	_	_	_	_	_
13	its	_	_	PRP$	_	_	_	_	_
14	bioactivity	_	_	NN	_	_	_	_	_
15	after	_	_	IN	_	_	_	_	_
16	the	_	_	DT	_	_	_	_	_
17	modification	_	_	NN	_	_	_	_	_
18	was	_	_	VBD	_	_	_	_	_
19	not	_	_	RB	_	_	_	_	_
20	evaluated	_	_	VBN	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	immunosuppressive	_	_	JJ	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	antimalarial	_	_	JJ	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	and	_	_	CC	_	_	_	_	_
7	pro-cytotoxic	_	_	JJ	_	_	_	_	_
8	bacterial	_	_	JJ	_	_	_	_	_
9	prodigiosin	_	_	NN	_	_	_	_	_
10	was	_	_	VBD	_	_	_	_	_
11	recently	_	_	RB	_	_	_	_	_
12	described	_	_	VBN	_	_	_	_	_
13	as	_	_	IN	_	_	_	_	_
14	a	_	_	DT	_	_	_	_	_
15	potent	_	_	JJ	_	_	_	_	_
16	antimetastatic	_	_	JJ	_	_	_	_	_
17	and	_	_	CC	_	_	_	_	_
18	anticancer	_	_	JJ	_	_	_	_	_
19	agent	_	_	NN	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	It	_	_	PRP	_	_	_	_	_
2	can	_	_	MD	_	_	_	_	_
3	induce	_	_	VB	_	_	_	_	_
4	apoptosis	_	_	NN	_	_	_	_	_
5	in	_	_	IN	_	_	_	_	_
6	a	_	_	DT	_	_	_	_	_
7	wide	_	_	JJ	_	_	_	_	_
8	range	_	_	NN	_	_	_	_	_
9	of	_	_	IN	_	_	_	_	_
10	cancer	_	_	NN	_	_	_	_	_
11	cell	_	_	NN	_	_	_	_	_
12	lines	_	_	NNS	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	including	_	_	VBG	_	_	_	_	_
15	hematopoietic	_	_	JJ	_	_	_	_	_
16	cancer	_	_	NN	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	breast	_	_	NN	_	_	_	_	_
19	cancer	_	_	NN	_	_	_	_	_
20	,	_	_	,	_	_	_	_	_
21	gastric	_	_	JJ	_	_	_	_	_
22	cancer	_	_	NN	_	_	_	_	_
23	,	_	_	,	_	_	_	_	_
24	colon	_	_	NN	_	_	_	_	_
25	cancer	_	_	NN	_	_	_	_	_
26	,	_	_	,	_	_	_	_	_
27	lung	_	_	NN	_	_	_	_	_
28	cancer	_	_	NN	_	_	_	_	_
29	,	_	_	,	_	_	_	_	_
30	and	_	_	CC	_	_	_	_	_
31	rat	_	_	NN	_	_	_	_	_
32	hepatocellular	_	_	JJ	_	_	_	_	_
33	carcinoma	_	_	NN	_	_	_	_	_
34	cell	_	_	NN	_	_	_	_	_
35	lines	_	_	NNS	_	_	_	_	_
36	,	_	_	,	_	_	_	_	_
37	with	_	_	IN	_	_	_	_	_
38	no	_	_	DT	_	_	_	_	_
39	marked	_	_	VBN	_	_	_	_	_
40	toxicity	_	_	NN	_	_	_	_	_
41	in	_	_	IN	_	_	_	_	_
42	nonmalignant	_	_	JJ	_	_	_	_	_
43	cells	_	_	NNS	_	_	_	_	_
44	.	_	_	.	_	_	_	_	_


1	However	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	prodigiosin	_	_	NN	_	_	_	_	_
4	has	_	_	VBZ	_	_	_	_	_
5	not	_	_	RB	_	_	_	_	_
6	been	_	_	VBN	_	_	_	_	_
7	reported	_	_	VBN	_	_	_	_	_
8	for	_	_	IN	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	treatment	_	_	NN	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	choriocarcinoma	_	_	NN	_	_	_	_	_
13	yet	_	_	RB	_	_	_	_	_
14	.	_	_	.	_	_	_	_	_


1	It	_	_	PRP	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	selective	_	_	JJ	_	_	_	_	_
4	in	_	_	IN	_	_	_	_	_
5	promoting	_	_	VBG	_	_	_	_	_
6	apoptosis	_	_	NN	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	malignant	_	_	JJ	_	_	_	_	_
9	tumor	_	_	NN	_	_	_	_	_
10	cells	_	_	NNS	_	_	_	_	_
11	,	_	_	,	_	_	_	_	_
12	rendering	_	_	VBG	_	_	_	_	_
13	prodigiosin	_	_	NN	_	_	_	_	_
14	a	_	_	DT	_	_	_	_	_
15	promising	_	_	JJ	_	_	_	_	_
16	anticancer	_	_	NN	_	_	_	_	_
17	agent	_	_	NN	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	antitumor	_	_	JJ	_	_	_	_	_
3	mechanism	_	_	NN	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	prodigiosin	_	_	NN	_	_	_	_	_
6	is	_	_	VBZ	_	_	_	_	_
7	still	_	_	RB	_	_	_	_	_
8	unclear	_	_	JJ	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	especially	_	_	RB	_	_	_	_	_
11	in	_	_	IN	_	_	_	_	_
12	regard	_	_	NN	_	_	_	_	_
13	to	_	_	TO	_	_	_	_	_
14	newly	_	_	RB	_	_	_	_	_
15	acquired	_	_	VBN	_	_	_	_	_
16	prodigiosin	_	_	NN	_	_	_	_	_
17	produced	_	_	VBN	_	_	_	_	_
18	by	_	_	IN	_	_	_	_	_
19	a	_	_	DT	_	_	_	_	_
20	small	_	_	JJ	_	_	_	_	_
21	number	_	_	NN	_	_	_	_	_
22	of	_	_	IN	_	_	_	_	_
23	microorganisms	_	_	NNS	_	_	_	_	_
24	,	_	_	,	_	_	_	_	_
25	including	_	_	VBG	_	_	_	_	_
26	Serratia	_	_	NNP	_	_	_	_	_
27	marcescens	_	_	NNS	_	_	_	_	_
28	and	_	_	CC	_	_	_	_	_
29	other	_	_	JJ	_	_	_	_	_
30	bacteria	_	_	NNS	_	_	_	_	_
31	,	_	_	,	_	_	_	_	_
32	such	_	_	JJ	_	_	_	_	_
33	as	_	_	IN	_	_	_	_	_
34	Streptomyces	_	_	NNP	_	_	_	_	_
35	griseoviridis	_	_	FW	_	_	_	_	_
36	,	_	_	,	_	_	_	_	_
37	Serratia	_	_	NNP	_	_	_	_	_
38	spp.	_	_	NNS	_	_	_	_	_
39	,	_	_	,	_	_	_	_	_
40	Zooshikellarubidus	_	_	NNP	_	_	_	_	_
41	,	_	_	,	_	_	_	_	_
42	Vibrio	_	_	NNP	_	_	_	_	_
43	sp	_	_	NNP	_	_	_	_	_
44	.	_	_	.	_	_	_	_	_
45	,	_	_	,	_	_	_	_	_
46	Actinomycetes	_	_	NNP	_	_	_	_	_
47	,	_	_	,	_	_	_	_	_
48	and	_	_	CC	_	_	_	_	_
49	Hahella	_	_	NNP	_	_	_	_	_
50	chejuensis	_	_	NNP	_	_	_	_	_
51	.	_	_	.	_	_	_	_	_


1	Research	_	_	NN	_	_	_	_	_
2	on	_	_	IN	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	mechanism	_	_	NN	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	bacterial	_	_	JJ	_	_	_	_	_
7	origin	_	_	NN	_	_	_	_	_
8	prodigiosin	_	_	NN	_	_	_	_	_
9	is	_	_	VBZ	_	_	_	_	_
10	very	_	_	RB	_	_	_	_	_
11	important	_	_	JJ	_	_	_	_	_
12	for	_	_	IN	_	_	_	_	_
13	clinical	_	_	JJ	_	_	_	_	_
14	application	_	_	NN	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	drug	_	_	NN	_	_	_	_	_
17	development	_	_	NN	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	this	_	_	DT	_	_	_	_	_
3	study	_	_	NN	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	to	_	_	TO	_	_	_	_	_
6	develop	_	_	VB	_	_	_	_	_
7	a	_	_	DT	_	_	_	_	_
8	new	_	_	JJ	_	_	_	_	_
9	type	_	_	NN	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	targeted	_	_	VBN	_	_	_	_	_
12	drug	_	_	NN	_	_	_	_	_
13	delivery	_	_	NN	_	_	_	_	_
14	carrier	_	_	NN	_	_	_	_	_
15	material	_	_	NN	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	investigate	_	_	VB	_	_	_	_	_
18	the	_	_	DT	_	_	_	_	_
19	anticancer	_	_	NN	_	_	_	_	_
20	mechanism	_	_	NN	_	_	_	_	_
21	of	_	_	IN	_	_	_	_	_
22	prodigiosin	_	_	NN	_	_	_	_	_
23	,	_	_	,	_	_	_	_	_
24	we	_	_	PRP	_	_	_	_	_
25	first	_	_	RB	_	_	_	_	_
26	used	_	_	VBD	_	_	_	_	_
27	plCSA-BP	_	_	NNP	_	_	_	_	_
28	as	_	_	IN	_	_	_	_	_
29	a	_	_	DT	_	_	_	_	_
30	guide	_	_	NN	_	_	_	_	_
31	peptide	_	_	NN	_	_	_	_	_
32	to	_	_	TO	_	_	_	_	_
33	coat	_	_	VB	_	_	_	_	_
34	on	_	_	IN	_	_	_	_	_
35	the	_	_	DT	_	_	_	_	_
36	DGL	_	_	NN	_	_	_	_	_
37	vector	_	_	NN	_	_	_	_	_
38	for	_	_	IN	_	_	_	_	_
39	cancer-cell-targeted	_	_	JJ	_	_	_	_	_
40	delivery	_	_	NN	_	_	_	_	_
41	of	_	_	IN	_	_	_	_	_
42	prodigiosin	_	_	NN	_	_	_	_	_
43	produced	_	_	VBN	_	_	_	_	_
44	from	_	_	IN	_	_	_	_	_
45	Serratia	_	_	NNP	_	_	_	_	_
46	marcescens	_	_	NNS	_	_	_	_	_
47	subsp	_	_	FW	_	_	_	_	_
48	.	_	_	.	_	_	_	_	_
49	lawsoniana	_	_	FW	_	_	_	_	_
50	HDZK-BYSB107	_	_	NNP	_	_	_	_	_
51	.	_	_	.	_	_	_	_	_


1	Then	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	we	_	_	PRP	_	_	_	_	_
4	tested	_	_	VBD	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	binding	_	_	NN	_	_	_	_	_
7	ability	_	_	NN	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	newly	_	_	RB	_	_	_	_	_
11	developed	_	_	VBN	_	_	_	_	_
12	DGL/CSA-PNPs	_	_	NNP	_	_	_	_	_
13	and	_	_	CC	_	_	_	_	_
14	its	_	_	PRP$	_	_	_	_	_
15	anticancer	_	_	JJ	_	_	_	_	_
16	effect	_	_	NN	_	_	_	_	_
17	in	_	_	IN	_	_	_	_	_
18	vitro	_	_	FW	_	_	_	_	_
19	on	_	_	IN	_	_	_	_	_
20	a	_	_	DT	_	_	_	_	_
21	JEG3	_	_	NNP	_	_	_	_	_
22	choriocarcinoma	_	_	NN	_	_	_	_	_
23	cell	_	_	NN	_	_	_	_	_
24	line	_	_	NN	_	_	_	_	_
25	and	_	_	CC	_	_	_	_	_
26	in	_	_	IN	_	_	_	_	_
27	vivo	_	_	NN	_	_	_	_	_
28	on	_	_	IN	_	_	_	_	_
29	a	_	_	DT	_	_	_	_	_
30	tumor	_	_	NN	_	_	_	_	_
31	model	_	_	NN	_	_	_	_	_
32	,	_	_	,	_	_	_	_	_
33	respectively	_	_	RB	_	_	_	_	_
34	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	addition	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	mechanism	_	_	NN	_	_	_	_	_
6	responsible	_	_	JJ	_	_	_	_	_
7	for	_	_	IN	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	anticancer	_	_	NN	_	_	_	_	_
10	effect	_	_	NN	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	targeted	_	_	VBN	_	_	_	_	_
13	nano-prodigiosin	_	_	NN	_	_	_	_	_
14	was	_	_	VBD	_	_	_	_	_
15	also	_	_	RB	_	_	_	_	_
16	investigated	_	_	VBN	_	_	_	_	_
17	.	_	_	.	_	_	_	_	_


1	Overall	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	these	_	_	DT	_	_	_	_	_
4	findings	_	_	NNS	_	_	_	_	_
5	suggested	_	_	VBD	_	_	_	_	_
6	that	_	_	IN	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	DGL/CSA	_	_	NNP	_	_	_	_	_
9	vector	_	_	NN	_	_	_	_	_
10	is	_	_	VBZ	_	_	_	_	_
11	an	_	_	DT	_	_	_	_	_
12	excellent	_	_	JJ	_	_	_	_	_
13	cancer-specific-drug	_	_	NN	_	_	_	_	_
14	delivery	_	_	NN	_	_	_	_	_
15	carrier	_	_	NN	_	_	_	_	_
16	,	_	_	,	_	_	_	_	_
17	which	_	_	WDT	_	_	_	_	_
18	has	_	_	VBZ	_	_	_	_	_
19	great	_	_	JJ	_	_	_	_	_
20	potential	_	_	NN	_	_	_	_	_
21	as	_	_	IN	_	_	_	_	_
22	a	_	_	DT	_	_	_	_	_
23	novel	_	_	JJ	_	_	_	_	_
24	delivery	_	_	NN	_	_	_	_	_
25	system	_	_	NN	_	_	_	_	_
26	for	_	_	IN	_	_	_	_	_
27	the	_	_	DT	_	_	_	_	_
28	treatment	_	_	NN	_	_	_	_	_
29	of	_	_	IN	_	_	_	_	_
30	cancer	_	_	NN	_	_	_	_	_
31	.	_	_	.	_	_	_	_	_

